Biotech News
Related news
IMTXImmatics2026-08-18 11:00 EST
Immatics Announces Second Quarter 2026 Financial Results and Business Update
INBXInhibrx2026-08-13 20:04 EST
Inhibrx Reports Second Quarter 2026 Financial Results
FATEFate Therapeutics2026-08-13 12:30 EST
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
PRLDPrelude Therapeutics2026-08-11 11:00 EST
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
REGNRegeneron Pharmaceuticals2026-09-24 20:05 EST
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
TEVATeva Pharmaceutical Industries2026-09-23 20:45 EST
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
GNLXGenelux2026-08-13 20:20 EST
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
MGNXMacroGenics2026-08-13 20:05 EST
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
KURAKura Oncology2026-08-12 20:02 EST
Kura Oncology Reports Second Quarter 2026 Financial Results
ERASErasca2026-08-11 20:01 EST
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
Exelixis
Commercial Oncology Company Exelixis develops and commercializes therapies for genitourinary and gastrointestinal cancers. Revenue from its established cabozantinib franchise funds a broad effort to create additional oncology products and combinations. Cabozantinib Franchise Cabozantinib is the company’s principal commercial asset and is...
Recent company news
EXELExelixis2026-09-01 20:05 EST
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
EXELExelixis2026-08-31 18:30 EST
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
EXELExelixis2026-08-05 20:05 EST
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
EXELExelixis2026-07-22 20:30 EST
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
EXELExelixis2026-06-22 12:00 EST
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
Stock data
- Close
- 58.33 USD
- Market cap
- 12.2B USD
- Exchange
- NASDAQ
- Sector
- Small Molecule Drugs
- Location
- United States